




SpaceOAR Vue™ Hydrogel


Scan. See. Plan. Treat. **All via CT.**

SpaceOAR Vue Hydrogel is the next-generation hydrogel spacer that offers enhanced visibility via CT scan, designed to help physicians improve contouring accuracy and consistently position patients receiving prostate cancer radiation as compared to SpaceOAR™ Hydrogel.¹


SpaceOAR Vue Hydrogel in different image modalities



Computed Tomography image.*



kV Cone-beam Computed Tomography image.*
First Fraction



T2-weighted Magnetic Resonance image.*



kV Cone-beam Computed Tomography image.*
Last Fraction

The difference is clear



Optimize dosing plan

Visibility of the gel on a CT scan is designed to help to reduce under- or over-contouring of the prostate and rectum for improved accuracy, as compared to SpaceOAR Hydrogel, and helps optimize treatment planning.^{1,2}



Streamline workflow

Treatment planning can be done using CT only, reducing the need to acquire, reference and fuse MR and CT images during plan creation, and is designed to improve visualization of the target area during patient positioning using kV cone-beam CT.¹



Visible on CT

The radiopacity may provide a suitable imaging option to MRI for patients with implanted metallic devices.¹

What is SpaceOAR™ Hydrogel?

SpaceOAR Hydrogel is a clinically studied, PEG-based hydrogel that positions the rectum away from the prostate while helping to minimize cancer radiation therapy side effects. In a clinical study, SpaceOAR Hydrogel was shown to help minimize the impact on urinary, sexual and bowel quality of life for prostate cancer patients undergoing radiation therapy.³⁻⁵

SpaceOAR Vue Hydrogel delivers similar benefits of space as the SpaceOAR Hydrogel, plus the intended benefit of enhanced CT visibility.¹

	SpaceOAR™ Hydrogel	SpaceOAR Vue™ Hydrogel
Chemistry¹	PEG Hydrogel	PEG Hydrogel
Hydrogel water content	~90%	~90%
Visibility	MR, Ultrasound, limited CT visibility	MR, Ultrasound, Enhanced CT, Cone-beam CT visibility
Iodine content	0%	~1%
Degradation	Via Hydrolysis	Via Hydrolysis
In Vivo Stability	3 months	3 months
Absorption profile	~ 6 months	~ 6 months
Hydrogel color	Clear	Tan
Application	Dual Injection	Dual Injection



Ordering information

Product code	Description
SV-2101	SpaceOAR Vue Hydrogel System

To learn more, visit [bostonscientific.com/spaceoarvue](https://www.bostonscientific.com/spaceoarvue) or speak to your Boston Scientific representative.

* Dr. Jeff Michalski, MD (2020). Permission granted by Washington University Imaging.

1. Data on file with Boston Scientific.
2. Xu H, Gordon JJ, Siebers JV. Coverage-based treatment planning to accommodate delineation uncertainties in prostate cancer treatment. *Med Phys*. 2015 Sep;42(9):5435-5443.
3. Mariados N, Sylvester J, Shah D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: Dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. *Int J Radiat Oncol Biol Phys*. 2015 Aug 1;92(5):971-7.
4. Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: Final results of a phase III trial. *Int J Radiat Oncol Biol Phys*. 2017 Apr 1;97(5):976-85.
5. Hamstra DA, Mariados N, Sylvester J, et al. Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. *Pract Radiat Oncol*. 2018 Jan - Feb;8(1):e7-e15.

SpaceOAR and SpaceOAR Vue Hydrogels are intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR and SpaceOAR Vue Hydrogels to reduce the radiation dose delivered to the anterior rectum.

SpaceOAR and SpaceOAR Vue Hydrogels contain polyethylene glycol (PEG). SpaceOAR Vue Hydrogel contains iodine.

Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events.

As with any medical treatment, there are some risks involved with the use of SpaceOAR and SpaceOAR Vue Hydrogels. Potential complications associated with SpaceOAR and SpaceOAR Vue Hydrogels include, but are not limited to: pain associated with SpaceOAR and SpaceOAR Vue Hydrogels injection, pain or discomfort associated with SpaceOAR and SpaceOAR Vue Hydrogels, local inflammatory reactions, infection (including abscess), urinary retention, urgency, constipation (acute, chronic, or secondary to outlet perforation), rectal tenesmus/muscle spasm, mucosal damage, ulcers, fistula, perforation (including prostate, bladder, urethra, rectum), necrosis, allergic reaction (localized or more severe reaction, such as anaphylaxis), embolism (venous or arterial embolism is possible and may present outside of the pelvis, potentially impacting vital organs or extremities), syncope and bleeding. The occurrence of one or more of these complications may require treatment or surgical intervention. URO-989811-AB.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.

**Boston
Scientific**

Advancing science for life™

Boston Scientific Corporation
300 Boston Scientific Way
Marlborough, MA 01752-1234
www.BostonScientific.com

©2024 Boston Scientific Corporation
or its affiliates. All rights reserved.

URO-754706-AC JUN 2024